Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.
In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.
Global Vice President of Analytical & Research Development, Scott Zugel, spoke at Veranova’s SCALE Symposium, where he outlined key analytical strategies and challenges in ADC manufacturing in the pharmaceutical industry.
Dissolution-permeation testing is helping drug developers better predict how food affects oral drug absorption by measuring both drug solubilization and membrane permeation, reducing the risk of misleading results from dissolution data alone.
Outsourcing formulation development and manufacturing can help drug developers address complex dosage forms, scale-up risks, regulatory demands, and accelerated timelines by connecting projects with CDMO partners that offer specialized expertise, integrated workflows, and scalable manufacturing support.
Shaukat Ali, PhD, and Jim Huang, PhD, discuss as more new chemical entities coming out of discovery are poorly soluble (BCS Class II and IV), the scCO2 is taking an aim to find the desired solutions to help improve the bottleneck in the industry.
PharmaCircle is a leading provider of authoritative information, global insight, and expert analysis on the pharmaceutical, biotech, drug delivery technology and device, and animal health industries.
PharmaCircle’s premier database tracks drugs, biologics and combination products in all stages of development, connecting pipeline and product information with formulation and component details. The database delivers seamless integration of scientific, clinical, safety, regulatory, manufacturing and commercial information, and detailed analyses on over 9,000 drug delivery technologies and delivery devices.
Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.
In a recent panel discussion, GlobalData’s Director …
Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …
As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …
Why Early Development Requires a Different Decision Model
Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …
The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.
Key messages:
Start
…
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
July 22 – Transdermal/Topical
July 29 – Drug Delivery
August 5 – Injection Devices
August 12 – Lyophilization Manufacturing